Transdermal evaporation delivery system of praziquantelfor schistosomiasis japonicum chemotherapy

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2769-2777

  Wang, Lei ^a   Zheng, Xinsheng ^a   Fang, Yan ^a   Wang, Yi ^a   Duan, Cunzheng ^a   Yao, Baoan ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

Absorption; Chemotherapy; Evaporative delivery; HPLC; Pharmacodynamics; Praziquantel; Schistosomiasis; Solubility; Transdermal drug delivery

Indexed keywords

2 PHENOXYETHANOL; PRAZIQUANTEL; SOLVENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; COST; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; HUMAN; MORBIDITY; NONHUMAN; SCHISTOSOMIASIS JAPONICA; SKIN IRRITATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 79955592273     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22508     Document Type: Article

References (33)

1. WHO Expert Committee. 2002. Prevention and control of schistosomiasis and soil-transmitted helminthiasis. World Health Organ Tech Rep Ser 912:1-57.
2. Sayed A, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. 2008. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 14:407-412.
3. Shadan S. 2008. Drug discovery: Schistosome treatment. Nature 452:296.
4. Abdul-Ghani RA, Loutfy N, Hassan A. 2009. Experimentally promising antischistosomal drugs: A review of some drug candidates not reaching the clinical use. Parasitol Res 105:899-906.
5. Spear RC, Seto E, Remais J, Carlton EJ, Davis G, Qiu DC, Zhou XN, Song L. 2006. Fighting waterborne infectious diseases. Science 314:1081-1082.
6. Wang LD, Guo J, Wu XH, Chen HG, Wang TP, Zhu SP, Zhang Z, Steinmann P, Yang GJ. 2009. China's new strategy to block Schistosoma japonicum transmission: Experiences and impact beyond schistosomiasis. Trop Med Int Health 14:1475-1483.
7. Gray DJ, Williams GM, Li YS. 2007. A cluster-randomized bovine intervention trial against Schistosoma japonicum in the People's Republic of China: Design and baseline results. Am J Trop Med Hyg 77:866-874.
8. Bergquist R. 2008. A century of schistosomiasis research. Acta Trop 108:65-68.
9. Prausnitz MR, Langer R. 2008. Transdermal drug delivery. Nat Biotechnol 26:1261-1268.
10. Thomas BJ, Finin BC. 2004. The transdermal revolution. Drug Discov Today 9:697-703.
11. Vintiloiu A, Leroux JC. 2008. Organogels and their use in drug delivery-A review. J Control Release 125:179-192.
12. Godavarthy SS, Yerramsetty KM, Rachakonda VK, Neely VJ, Madihally SV, Robinson RL, Gasem AM. 2009. Design of improved permeation enhancers for transdermal drug delivery. J Pharm Sci 98:4085-4099.
13. Prausnitz MR, Mitragotri S, Langer R. 2004. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3:115-123.
14. Barry BW. 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14:101-107.
15. Zhou XQ, Liu DZ, Liu HY, Yang QL, Yao KD, Wang XY, Wang L, Yang XJ. 2010. Effect of low molecular weight chitosans on drug permeation through mouse skin: 1. Transdermal delivery of baicalin. J Pharm Sci 99:2991-2998.
16. Tanner T, Marks R. 2008. Delivering drugs by the transdermal route: Review and comment. Skin Res Technol 14:249-260.
17. EI, Maghraby GM, Barry BW, Williams AC. 2008. Liposomes and skin: From drug delivery to model membranes. Eur J Pharm Sci 34:203-222.
18. Azarmi S, Roa W, Lobenberg R. 2007. Current perspectives in dissolution testing of conventional and novel dosage forms. Int J Pharm 328:12-21.
19. Narishetty STK, Panchagnula R. 2004. Transdermal delivery of zidovudine effect of terpenes and their mechanism of action. J Control Release 95:367-379.
20. Khafagy ES, Morishita M, Onuki Y, Takayama K. 2007. Current challenges in noninvasive insulin delivery systems: A comparative review. Adv Drug Deliv Rev 59:152-1546.
21. Chen MG. 2005. Use of praziquantel for clinical treatment and morbidity control of Schistosomiasis japonica in China: A review of 30 years' experience. Acta Trop 96:168-176.
22. Ribeiro-dos-Santos G, Verjovsky-Almeida S, Leite LCC. 2006. Schistosomiasis-A century searching for chemotherapeutic drugs. Parasitol Res 99:505-521.
23. Taylor LJ, Lee RS, Long M, Rawlings AV, Tubek J, Whitehead L, Moss GP. 2002. Effect of occlusion on the percutaneous penetration of linoleic acid and glycerol. Int J Pharm 249:157-164.
24. Wang C. 2000. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A general clinical research center study. J Clin Endocrinol Metab 85:964-969.
25. Liu HZ, Wang YJ, Lang YY, Yao HM, Dong Y, Li SM. 2009. Bicontinuous cyclosporin a loaded water-AOT/tween 85-isopropylmyristate microemulsion: Structural characterization and dermal pharmacokinetics in vivo. J Pharm Sci 98:1167-1176.
26. Amnuaikit C, Ikeuchi I, Ogawara K, Higaki K, Kimura T. 2005. Skin permeation of propranolol from polymeric film containing terpene enhancer for transdermal use. Int J Pharm 289:167-178.
27. Grice JE, Ciotti S, Weiner N, Lockwood P, Cross SE, Roberts M. 2010. Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro. J Pharm Sci 99:712-718.
28. Tanner T, Marks R. 2008. Delivering drugs by the transdermal route: Review and comment. Skin Res Technol 14:249-260.
29. Degim IT. 2006. New tools and approaches for predicting skin permeability. Drug Discov Today 11:517-23.
30. Barry BW. 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14:101-114.
31. Williams AC, Barry BW. 2004. Penetration enhancers. Adv Drug Deliv Rev 56:603-618.
32. Levine IN. 1988. Physical Chemistry. 3rd ed. New York: McGraw-Hill Co., pp 234-235.
33. Finin BC, Morgan TM. 1999. Transdermal penetration enhancers: Applications, limitations, and potential. J Pharm Sci 88:955-958.